JP2002542812A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002542812A5 JP2002542812A5 JP2000615652A JP2000615652A JP2002542812A5 JP 2002542812 A5 JP2002542812 A5 JP 2002542812A5 JP 2000615652 A JP2000615652 A JP 2000615652A JP 2000615652 A JP2000615652 A JP 2000615652A JP 2002542812 A5 JP2002542812 A5 JP 2002542812A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- molecule
- protease
- based system
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 description 22
- 238000000034 method Methods 0.000 description 14
- 108091023040 Transcription factor Proteins 0.000 description 9
- 102000040945 Transcription factor Human genes 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 101800001838 Serine protease/helicase NS3 Proteins 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 108010076039 Polyproteins Proteins 0.000 description 4
- 108700008625 Reporter Genes Proteins 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 2
- 101800001014 Non-structural protein 5A Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 101800001020 Non-structural protein 4A Proteins 0.000 description 1
- 101800001019 Non-structural protein 4B Proteins 0.000 description 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 1
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 108700012707 hepatitis C virus NS3 Proteins 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13236099P | 1999-05-04 | 1999-05-04 | |
| US60/132,360 | 1999-05-04 | ||
| PCT/CA2000/000496 WO2000066623A2 (en) | 1999-05-04 | 2000-05-01 | Surrogate cell-based system and method for assaying the activity of hepatitis c virus ns3 protease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002542812A JP2002542812A (ja) | 2002-12-17 |
| JP2002542812A5 true JP2002542812A5 (https=) | 2007-06-21 |
| JP4782927B2 JP4782927B2 (ja) | 2011-09-28 |
Family
ID=22453660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000615652A Expired - Fee Related JP4782927B2 (ja) | 1999-05-04 | 2000-05-01 | 代理細胞ベースシステム及びｃ型肝炎ウイルスｎｓ３プロテアーゼの活性を評価する方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US7276373B2 (https=) |
| EP (1) | EP1177211B1 (https=) |
| JP (1) | JP4782927B2 (https=) |
| AT (1) | ATE386746T1 (https=) |
| AU (1) | AU772386B2 (https=) |
| CA (1) | CA2365262C (https=) |
| DE (1) | DE60038113T2 (https=) |
| DK (1) | DK1177211T3 (https=) |
| ES (1) | ES2300262T3 (https=) |
| HU (1) | HUP0200945A3 (https=) |
| IL (2) | IL145376A0 (https=) |
| MX (1) | MXPA01011045A (https=) |
| NZ (1) | NZ515861A (https=) |
| WO (1) | WO2000066623A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2365262C (en) * | 1999-05-04 | 2008-06-10 | Boehringer Ingelheim (Canada) Ltd. | Surrogate cell-based system and method for assaying the activity of hepatitis c virus ns3 protease |
| AU5920400A (en) * | 1999-07-07 | 2001-01-22 | Du Pont Pharmaceuticals Company | Cell-based assay systems for examining hcv ns3 protease activity |
| US6986892B1 (en) | 1999-11-24 | 2006-01-17 | Chiron Corporation | Immunogenic Hepatitis C virus non-structural polypeptides |
| WO2001038360A2 (en) * | 1999-11-24 | 2001-05-31 | Chiron Corporation | Novel hcv non-structural polypeptide |
| US6921634B2 (en) * | 1999-12-23 | 2005-07-26 | Board Of Regents, The University Of Texas System | Replication competent hepatitus C virus and methods of use |
| CA2370803A1 (en) * | 2000-02-25 | 2001-08-30 | Cambridge Drug Discovery, Ltd. | Methods for identifying a protease inhibitor |
| MXPA03005638A (es) | 2000-12-22 | 2004-04-05 | Boehringer Ingelheim Ca Ltd | Auto replicacion de la molecula de arn de virus de la hepatitis c. |
| DE10234418A1 (de) * | 2002-07-29 | 2004-02-12 | Bayer Ag | Verfahren zur Untersuchung und Beurteilung von Virusenzymen im HTS |
| EP1670415A4 (en) * | 2003-09-12 | 2007-12-05 | Vertex Pharma | ANIMAL MODEL FOR STUDYING PROTEASES ACTIVITY AND HEPATIC DISORDERS |
| WO2005037214A2 (en) | 2003-10-14 | 2005-04-28 | Intermune, Inc. | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication |
| MX2008001166A (es) | 2005-07-25 | 2008-03-18 | Intermune Inc | Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c. |
| AU2006301966A1 (en) | 2005-10-11 | 2007-04-19 | Array Biopharma, Inc. | Compounds and methods for inhibiting hepatitis C viral replication |
| EP2392589A3 (en) | 2005-11-11 | 2012-06-20 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
| US7705138B2 (en) | 2005-11-11 | 2010-04-27 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
| WO2013027217A1 (en) * | 2011-08-22 | 2013-02-28 | Ramot At Tel-Aviv University Ltd. | Zymoxins and methods of using the same |
| US9353423B2 (en) | 2012-11-07 | 2016-05-31 | Gilead Sciences, Inc. | HCV genotype 6 replicons |
| US20210087548A1 (en) * | 2017-07-24 | 2021-03-25 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and Methods for Inducing Protein Function |
| WO2022094463A1 (en) * | 2020-11-02 | 2022-05-05 | Regents Of The University Of Minnesota | Live cell assay for protease inhibition |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3269642B2 (ja) * | 1990-06-25 | 2002-03-25 | 財団法人阪大微生物病研究会 | 非Ａ非Ｂ型肝炎ウイルス遺伝子ｃＤＮＡおよび抗原ポリペプチド |
| AU652941B2 (en) * | 1990-06-25 | 1994-09-15 | Research Foundation For Microbial Diseases Of Osaka University, The | Non-A, Non-B hepatitis virus particles |
| US5861267A (en) * | 1995-05-01 | 1999-01-19 | Vertex Pharmaceuticals Incorporated | Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity |
| IT1277914B1 (it) * | 1995-08-22 | 1997-11-12 | Angeletti P Ist Richerche Bio | Procedimento per produrre - in forma pura e in quantita' elevate - polipeptidi con l'attivita' proteolitica della proteasi ns3 di hcv, e |
| KR100209095B1 (ko) * | 1996-06-28 | 1999-07-15 | 성재갑 | C형 간염 바이러스의 프로테아제의 활성을 측정할 수 있는 c형 간염 대체 바이러스, 그 재조합 유전자 및 그 용도 |
| US6280940B1 (en) * | 1998-08-05 | 2001-08-28 | Agouron Pharmaceuticals, Inc. | Reporter gene system for use in cell-based assessment of inhibitors of the Hepatitis C virus protease |
| US6117639A (en) * | 1998-08-31 | 2000-09-12 | Vertex Pharmaceuticals Incorporated | Fusion proteins, DNA molecules, vectors, and host cells useful for measuring protease activity |
| CA2365262C (en) * | 1999-05-04 | 2008-06-10 | Boehringer Ingelheim (Canada) Ltd. | Surrogate cell-based system and method for assaying the activity of hepatitis c virus ns3 protease |
-
2000
- 2000-05-01 CA CA002365262A patent/CA2365262C/en not_active Expired - Fee Related
- 2000-05-01 MX MXPA01011045A patent/MXPA01011045A/es active IP Right Grant
- 2000-05-01 DE DE60038113T patent/DE60038113T2/de not_active Expired - Lifetime
- 2000-05-01 NZ NZ515861A patent/NZ515861A/en not_active IP Right Cessation
- 2000-05-01 AT AT00922396T patent/ATE386746T1/de active
- 2000-05-01 ES ES00922396T patent/ES2300262T3/es not_active Expired - Lifetime
- 2000-05-01 IL IL14537600A patent/IL145376A0/xx unknown
- 2000-05-01 DK DK00922396T patent/DK1177211T3/da active
- 2000-05-01 EP EP00922396A patent/EP1177211B1/en not_active Expired - Lifetime
- 2000-05-01 HU HU0200945A patent/HUP0200945A3/hu unknown
- 2000-05-01 WO PCT/CA2000/000496 patent/WO2000066623A2/en not_active Ceased
- 2000-05-01 JP JP2000615652A patent/JP4782927B2/ja not_active Expired - Fee Related
- 2000-05-01 AU AU42825/00A patent/AU772386B2/en not_active Ceased
-
2001
- 2001-09-11 IL IL145376A patent/IL145376A/en not_active IP Right Cessation
-
2002
- 2002-12-23 US US10/328,206 patent/US7276373B2/en not_active Expired - Lifetime
- 2002-12-23 US US10/328,127 patent/US20030162168A1/en not_active Abandoned
-
2005
- 2005-05-27 US US11/140,379 patent/US7838207B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002542812A5 (https=) | ||
| JP4903929B2 (ja) | Ｃ型肝炎ウイルス細胞培養系、ｃ型肝炎ウイルス−ｒｎａ−構築物、細胞培養系または構築物の使用、ｃ型肝炎ウイルス−ｒｎａ−構築物の細胞培養に適合した突然変異体を獲得する方法、ｃ型肝炎ウイルス−全長ゲノム、ｃ型肝炎ウイルス−部分ゲノム、または任意のｃ型肝炎ウイルス−構築物の突然変異体の製法、細胞培養に適合したｃ型肝炎ウイルス−構築物、その突然変異体、ｃ型肝炎ウイルス−全長ゲノムの突然変異体、ｃ型肝炎ウイルス粒子またはウイルス様粒子、およびこれで感染した細胞 | |
| Jones et al. | Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus | |
| Wang et al. | Core protein-coding sequence, but not core protein, modulates the efficiency of cap-independent translation directed by the internal ribosome entry site of hepatitis C virus | |
| Berger et al. | Secreted placental alkaline phosphatase: a powerful new quantitative indicator of gene expression in eukaryotic cells | |
| Yi et al. | Subgenomic hepatitis C virus replicons inducing expression of a secreted enzymatic reporter protein | |
| US7276373B2 (en) | Surrogate cell-based system and method for assaying the activity of hepatitis C virus NS3 protease | |
| US20090203008A1 (en) | Rapid method to determine inhibitor sensitivity of NS3/4A protease sequences cloned from clinical samples | |
| Shapira et al. | Removal of hepatitis C virus-infected cells by a zymogenized bacterial toxin | |
| JP2004516039A (ja) | Ｃ型肝炎ウイルスからの自己複製ｒｎａ分子 | |
| US20180127800A1 (en) | Compositions and methods for identifying zika enzyme inhibitors | |
| Lobigs | Proteolytic processing of a Murray Valley encephalitis virus non-structural polyprotein segment containing the viral proteinase: accumulation of a NS3-4A precursor which requires mature NS3 for efficient processing | |
| Wang et al. | Conserved C-terminal threonine of hepatitis C virus NS3 regulates autoproteolysis and prevents product inhibition | |
| Whitney et al. | A collaborative screening program for the discovery of inhibitors of HCV NS2/3 cis-cleaving protease activity | |
| JP3878132B2 (ja) | 精製活性型ｈｃｖｎｓ２／３プロテアーゼ | |
| Pacini et al. | Reporter substrates for assessing the activity of the hepatitis C virus NS3-4A serine protease in living cells | |
| EP1499748B1 (en) | Hepatitis c virus assay systems | |
| Klump et al. | Proteolytically Active 2A Proteinase of Human Rhinovirus 2 Is Toxic forSaccharomyces cerevisiaebut Does Not Cleave the Homologues of eIF-4γin Vivoorin Vitro | |
| Song et al. | Development of an in vivo assay system suitable for screening inhibitors of hepatitis C viral protease | |
| EP1360276A2 (en) | In vitro system for replication of rna-dependent rna polymerase (rdrp) viruses | |
| Enomoto et al. | Establishment of a New Hepatitis C Virus-1 b Replicon | |
| TW200424215A (en) | Systems for screening anti-hepatitis drugs | |
| AU2002224688A1 (en) | Purified active HCV NS2/3 protease | |
| AU2002240214A1 (en) | In vitro system for replication of RNA-dependent RNA polymerase (RDRP) viruses |